Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) constitute an important pharmacotherapeutic class which, over the past decade, have expanded in application to a panoply of medical conditions. They have been tested for neurodegenerative diseases such as Alzheimer's to reduce the inflammation and also in the attempt to abrogate amyloid deposition. However, the use of NSAID as aggregation inhibitors has not been extensively studied in pancreatic amyloid deposition. Pancreatic amyloidosis involves the misfolding of islet amyloid polypeptide (IAPP) and contributes to the progression of type
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Introduction
Diseases involving abnormal folding of proteins and conversion to an insoluble state are numerous in human and veterinary medicine, with more than thirty diseases related specifically to amyloid formation, including Alzheimer's disease (AD), type 2 diabetes, Parkinson's disease, prion disease and familial amyloidosis (Sipe et al. 2014 ).
Protein misfolding, in amyloidosis, is characterized by a monomeric protein which is assembled into β-sheet insoluble fibrils (Hard and Lendel 2012) . These amyloid deposits damage the cell membrane, inducing reactive oxygen species and apoptosis Jayasinghe and Langen 2007; Jelinek and Sheynis 2010) . Amyloid deposits may be localized in a tissue or generalized in different organs depending on the origin of the constitutive protein (Hard and Lendel 2012; Sipe et al. 2014 ).
Amyloidogenic proteins do not share a common amino acid sequence nor a similar secondary or tertiary conformation in the native state. However, all types of amyloid have in common the formation of fibrils, with unique physicochemical characteristics as follows: a diameter of 5-15 nm, a cross-β sheet quaternary structure, a poor solubility in acidic or basic environments, and a resistance to extreme temperatures (Cheng et al. 2013; Hard and Lendel 2012) . Several amyloidogenic proteins, such as TTR, are rich in beta-sheet in their soluble native conformation.
D r a f t
In the past few decades, extensive effort has been expended to understand the pathophysiology of amyloidosis related to degenerative diseases such as Alzheimer's disease (AD) and type 2 diabetes, potentially leading to new therapeutic strategies.
Although the actual details of many of the steps are unclear, the assembly of amyloidogenic proteins into a fibrillar structure occurs in stepwise fashion. An apparent early step in the aggregation is the formation of a set of conformationally diverse oligomers (Brender et al. 2015; Buchanan et al. 2014; Mishra et al. 2009 ), present at low abundance (Suzuki et al. 2012) , with structures different from either the native largely unstructured peptide (Reddy et al. 2010; Williamson and Miranker 2007; Yonemoto et al. 2008) or the mature amyloid fiber (Luca et al. 2007 ). Subsequently, the oligomers assemble into a mature fibril. At this point, the proteins have a β-sheet secondary structure (Luca et al. 2007; Westermark et al. 2011) . In parallel, these oligomers act as a seed, thereby initiating the aggregation and propagation of fibrils (Westermark et al. 2011) . Although several factors can influence the fibrillar aggregation, the precise mechanisms are not clearly identified. More research on the mechanisms underlying the fibrillar aggregation will be crucial in the discovery of new antiamyloidogenic agents. The development of an inhibitor is also challenging considering that it doesn't require to stabilize solely the native protein or the oligomers (Cheng et al. 2013; Hard and Lendel 2012; Porat et al. 2006) . The most common approach in pharmaceutical discovery research against amyloidogenic proteins involves exploring inhibitors of fibrillar deposition (Cheng et al. 2013; Hard and Lendel 2012; Porat et al. 2006 ). Perhaps, the best way to inhibit amyloid formation is by stabilizing the native conformation by small molecules, i.e. Tafamidis and TTR. (Dong et al. 2014; Lim et al. 2000; Yan et al. 2003) .
Whether selective COX-2 inhibitors have clinical benefits with direct effects on brain amyloid deposition remain to be elucidated. Interestingly, the diarylamine classes, including diclofenac, were effective in inhibiting fibril formation related to other diseases, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP), that involve transthyretin (TTR) amyloid formation (Oza et al. 2002) . Others studies were performed in the attempt to inhibit amyloid formation related to type 2 diabetes. Amyloid deposits localized in the islets involve the misfolding of islet amyloid polypeptide (IAPP) and contribute to the progression of type 2 diabetes in human and diabetes mellitus in adult cats (Hoppener et al. 2002; Jaikaran and Clark 2001; O'Brien et al. 1993; Westermark et al. 2011) . The effect of aspirin and ketoprofen were examined in pancreatic amyloidosis (Tu et al. 2014) . However, these drugs failed to inhibit amyloid formation or to disaggregate preformed fibrils (Tu et al. 2014 ).
The implication of NSAIDs as IAPP aggregation inhibitors has not been extensively explored and their clinical benefits remain to be elucidated. This study focusses on the investigation of NSAIDs in inhibiting amyloidosis related to type 2 diabetes, with a potential therapeutic target of hIAPP fibrils. We describe the inhibition activity of a number of commercially available NSAIDs on hIAPP fibrils formation. The information gained from this study will help further structure-activity relationship studies for designing new derivatives with improved potency. 
Cell line and culture
INS-1 (rat insulinoma) cells were purchased from AddexBio (San Diego, CA) and cultured in RPMI1640 medium supplemented with 10 mM HEPES, 2 mM L-glutamine, 1X sodium pyruvate, 50 µM 2-mercaptoethanol, 100 U/mL streptomycin, 100 U/mL of penicillin G and 10 % fetal bovine serum (Wisent Inc., St-Bruno, Qc, Canada). Cells were maintained in a moisture saturated atmosphere at 37 °C under 5% CO 2 .
Peptide synthesis
Synthetic hIAPP (1-37) was obtained from Peptidogen International Corp (Brossard, Qc, Canada) . Peptides were prepared, as previously published, with a microwave peptide synthesizer, using 9-fluornylmethoxycarbonyl (Fmoc) chemistry, and Fmoc-protected pseudoproline dipeptide derivatives were incorporated to facilitate the synthesis (Cao et al. 2013 ). The peptides were purified by reverse-phase HPLC using a D r a f t 7 C18 preparative column. The identity of the pure products was confirmed by mass spectrometry using a Bruker MALDI-TOF MS. Analytical HPLC was used to check the purity of the peptides (≥ 95%) before each experiment. The purified peptide was lyophilized.
Sample preparation
hIAPP stock solutions were prepared by dissolving the hIAPP peptide at 1 mM in 100% HFIP and incubating for at least 12 h. For the ThT kinetics, circular dichroism spectrometry and photo-induced cross-linking based oligomerization assays, hIAPP peptide stock solutions were prepared by dissolving peptides at 1 mM in 100% HFIP. For the cytotoxicity assays, the IAPP peptide stock solutions of 1 mM were divided in aliquots to obtain the desired final concentration and were air-dried. Aliquots of the stock solutions were dried to remove organic solvents and suspended in 10 mM PBS buffer (pH 7.4) at the desired concentration. hIAPP was dissolved in DMSO and PBS.
DMSO was used at a final concentration lower than 0.1 % (v/v) to avoid cell toxicity. measurements were taken at room temperature every 2 min with 10 seconds shaking prior measurements over 6 h. Short agitation measurements were obtained by shaking the plate prior measurement for 5 sec to ensure proper mixing and subsequently measuring the fluorescence intensity every 10 min. Samples were measured in three replicates and the experiments were repeated three times using different IAPP stock solutions. For each time point, arbitrary units of fluorescence were calculated from the mean values normalized against the maximum value in each completed assay. Arbitrarily, the maximum value (100 %) for the fluorescence intensity was established for hIAPP peptide. The lag time and the T 50 were calculated as previously described (Zhang et al. 2011 ).
Far-Ultraviolet (UV) circular discroism (CD)
D r a f t 9 CD spectra of the secondary structure of hIAPP samples were recorded at 25 °C under a constant flow of N 2 using a JASCO-810 spectropolarimeter (Jasco, Easton, MD).
Spectra were recorded over a wavelength range of 190-250 nm using a quartz cuvette of 1 mm path length and an instrument scanning speed of 100 nm/min, with a response time of 2 sec and a bandwidth of 1 nm. Samples were not agitated. All IAPP samples were dissolved to a final concentration of 15 µM in 10 mM PBS (pH 7.4) and 1% HFIP, and where appropriate, the samples contained different drug treatments at a final concentration of 25 µM. Each result is given as the average scans taken of three measurements at room temperature. The data were converted to mean residue ellipticity (θ) and analyzed using the software CDPro as previously described (Sreerama and Woody 2004) . All CD spectra were averaged, smoothed and baseline-corrected for signal contributions due to the buffer.
Photo-induced cross-linking (PICUP) assay
hIAPP was diluted in 10 mM phosphate buffer (pH 7.4) to a final concentration of 250 µM peptide and 1% HFIP. The peptide solution was sonicated for 1 min. Drugs were also freshly dissolved in DMSO and added to the peptide solution at a molar ratio of 1:5 (hIAPP:compound). The control consisted of samples that were photo-cross-linked using the PICUP method as described (Bitan and Teplow 2004) . The reaction buffer consisted of 938 µM Ru(bpy), 18.8 mM ammonium persulfate and 250 µM hIAPP. Cross-linking was induced by irradiation, for 3 s, of the mixture, at a final volume of 60 µL, with a 150 W incandescent lamp installed in a homemade dark-box. After irradiation, 25 µL of Lammeli loading buffer was immediately added to the solution, followed by incubation at D r a f t 37 °C for 15 min. The cross-linked samples were separated on a 16% Tricine-urea gel and visualized by silver staining.
Cell viability assay
Cells were maintained in a 37 °C, 5% CO 2 incubator, in exponential growth, for the duration of experimentation. 
Statistical analysis
All results in Table 2, Table 3 and Figure 4 were presented as mean ± SD. For the cell viability assays, data were analyzed by the one-way analysis of variance with Dunnett's multiple comparison between IAPP and several drug treatments. Differences were considered statistically significant at p < 0.05 and p < 0.001.
Results
NSAIDs are effective inhibitors of hIAPP aggregation Table 1 displays the classification and molecular structure of NSAIDs used in this study. The effects of NSAIDs on the kinetics of hIAPP fibrillization using thioflavin T (ThT) fluorescence assay were examined. ThT binds to the cross β-structure of amyloid fibrils, theoretically in the surface grooves generated by stacking parallel β-sheets (Buell et al. 2010) . The self-quenching of the fluorescent dye is relieved by the conformational changes induced by amyloid binding, resulting in fluorescence enhancement (Buell et al. 2010 ). The expected sigmoidal time course is observed when hIAPP is incubated without drug treatments ( Fig. 1 ) (Paulsson et al. 2011 ). In the absence of drugs, the time required to reach half of the total fluorescence signal (T 50 ) was 39.9 ± 0.2 min for samples with longer agitation during measurement and 105,3 ± 0.7 min for samples with shorter agitation during measurement. For both samples, diclofenac and phenylbutazone significantly increased the T 50 at a molar ratio of 1:10 (10 µM of hIAPP:100 µM of drug) D r a f t (Table 2 and Table 4 ). Positive controls (resveratrol, silibinin) (Cheng et al. 2012; Jiang et al. 2011 ) and NSAIDs treatments shown in Fig. 1 (celecoxib, diclofenac, indomethacin, meloxicam, niflumic acid, nimesulide, phenylbutazone, piroxicam, sulindac, tenoxicam) significantly reduced the fluorescence intensity at a molar ratio of 1:10. The curves in these graphs exhibit a different slope for the treated and untreated groups. The time during which no significant fibril formation occurs followed by a rapid growth phase (lag time) was shorter for meloxicam, nimesulide, piroxicam, sulindac, tenoxicam, resveratrol and silibinin in Table 4 . Interestingly, diclofenac and phenylbutazone prolonged the lag time. NSAID treatments such as niflumic acid, nimesulide and sulindac maintained their efficacy in reducing the amyloidogenicity of hIAPP fibrils using a molar ration of 1:5 (10 µM of hIAPP:50 µM of drug). The ThT fluorescence of h-IAPP was reduced by the presence of 25 µM and 50 µM of meloxicam (Table 3) . Other NSAIDs, such as COX-2 inhibitors, had no detectable effect on the kinetics of amyloid formation and the final fluorescence intensity.
NSAIDs induce secondary structure changes of hIAPP
Amyloid formation involves the oligomerization of hIAPP and the formation of mature linear fibrils by the oligomer self-assembly (Buchanan et al. 2013; Cao et al. 2013; Hard and Lendel 2012) . The first and the last steps are characterized by the α-helical structure and β-sheet structure, respectively (Buchanan et al. 2013; Cao et al. 2013; Hard and Lendel 2012) . To monitor the effect of NSAIDs on hIAPP oligomerization and self-assembly into mature fibrils, the secondary structure was determined by Far-UV CD. Spectra were recorded using hIAPP at 15 µM and drug After an incubation time of 1h, a major negative peak at 220 nm was observed, indicative of a predominant β-sheet secondary structure. The CD spectra recorded at an incubation time of 1h were shown to compare the untreated and treated conditions (Fig. 2) .
The CD spectra of niflumic acid, phenylbutazone, and nimesulide showed evidence of extensive β-sheet formation at the final time point, suggesting the decrease in
ThT fluorescence intensity may be due to the displacement of the ThT dye (Suzuki et al. 2012) or to the formation of non-fibrillar but still β-sheet aggregates.
The spectrum of IAPP in presence of diclofenac, piroxicam and, to a lesser extent, sulindac shows the two negative peaks at 208 nm and around 220-221 nm characteristic of the exciton splitting found in predominantly α-helical structures. Silibinin, tenoxicam, and meloxicam showed a mixed β-sheet/random coil spectra at the final time-point, indicating a delayed transition or the formation of more disordered aggregates than the fibers produced in the absence of these inhibitors. Resveratrol showed a more complicated, less easily interpreted spectrum.
NSAIDs abrogate the oligomerization of hIAPP
Soluble oligomeric species of hIAPP contribute to the deleterious cellular effect by binding to bilipidic membranes leading to cell membrane leakage (Buchanan et al. 2013; Cao et al. 2013; Gurlo et al. 2010; Jayasinghe and Langen 2007; Jelinek and Sheynis 2010; Khemtemourian et al. 2008) . PICUP assays were performed to determine the effect of NSAIDs on the oligomerization of hIAPP. The potent NSAIDs in affecting hIAPP aggregate were tested at a molar ratio of 1:5. Without NSAID and irradiation treatments, hIAPP was predominantly in a monomeric state. When hIAPP was subjected to light exposure, a mixture of monomer, dimer, trimer, tetramer and higher oligomers was obtained (Fig. 3) , illustrating the strong oligomerization potential of hIAPP. The oligomerization of hIAPP was inhibited for samples treated with resveratrol and silibinin, consistent with previous experiments (Cheng et al. 2012; Jiang et al. 2011 ).
The oligomerization of hIAPP was abrogated following a treatment with diclofenac. The second most potent inhibitor was sulindac. The dimeric state was observed in samples treated with the oxicam family (meloxicam, piroxicam and tenoxicam). Niflumic acid, nimesulide and phenylbutazone were able to partially block the oligomerization process.
NSAIDs protect INS-1 cells from toxic hIAPP fibrils
The potential protective effect of NSAIDs against hIAPP fibrils cytotoxicity was investigated. Pre-incubated hIAPP was added to INS-1 cells for 24 h in the presence or absence of increasing concentration of NSAIDs (Fig. 4) . Resveratrol protected cells at The protective effect of resveratrol and meloxicam against hIAPP aggregation has a narrow therapeutic window. Niflumic acid and nimesulide are toxic at concentrations affecting hIAPP aggregation. Thus, a protective effect of these drugs was not observed.
Discussion
The global prevalence of type 2 diabetes among adults population worldwide was approximated to be 9 % in 2014 (www.who.int/mediacentre/factsheets/fs312/en/). Up to 1.5 million deaths were estimated in 2012 to be directly attributed to type 2 diabetes 
D r a f t
Non-steroidal anti-inflammatory drugs (NSAIDs) have been used in a plethora of inflammatory conditions based on the inhibition of COX-2. There are contradictory reports in regard to the amyloid inhibitory effect of NSAIDs in Alzheimer's disease (AD) (Browne et al. 2006; Cole et al. 2004; Dong et al. 2014; Hillmann et al. 2012; Lim et al. 2000; McKee et al. 2008; Netland et al. 1998; Yan et al. 2003) . Previous investigations reported that the Aβ-amyloid induces inflammation, but the inflammatory responses occur earlier than the formation of the senile plaque (Cole et al. 2004 ). The physiopathology underlying AD involves an inflammatory process that has not been fully understood and clinical studies have been reported conflicting data (Browne et al. 2006; Cole et al. 2004; Dong et al. 2014; Hillmann et al. 2012; Lim et al. 2000; McKee et al. 2008; Netland et al. 1998; Yan et al. 2003) . Rofecoxib, a selective COX-2 inhibitor, failed to reduce the progression of cognitive impairment in patients suffering from mild or moderate AD (Aisen et al. 2003) . However, another study reported that COX-2 inhibition improves the suppression of memory associated with Aβ-amyloid deposition in patients with AD. In a transgenic mouse model of AD, ibuprofen, a non-selective COX-2 inhibitor, reduced AD-type pathologic change after 6 months of treatment in comparison with an untreated control group (Lim et al. 2000) . Whether selective COX-2 inhibitors have clinical benefit remains to be elucidated.
There are limits to the interpretation of each assay that was performed, hence it is critical to consider the results of the different assays altogether before drawing conclusions. This study highlights compounds and structures of potential interest. For practical purposes, assays were completed within few hours (shorter and longer kinetics).
ThT assays can be optimized by simple variations of initial testing conditions, compromising between physiologically relevant conditions and the need for a relatively fast reaction. When high-throughput screening of small molecules in relation to aggregation is used, it is important to complement the study with other assays, particularly a cell-based assay. Drugs may be capable of displacing ThT binding, resulting in false positives (false hit compound). Which is why, we complemented the Thioflavin T-based fluorescence assays with the Far-UV circular discroism spectrometry, the photo-induced cross-linking (PICUP) assay and a biological assay. There are some limits in the interpretation of CD spectra for the apparent decrease at 220 nm due to the absorbance of the inhibitors, which stresses the importance of performing multiple assays before drawing conclusions on the potential efficacy of compounds. The cell-based assay used in our study involved pre-formed hIAPP amyloid before the drug challenge.
Consequently, the effective drugs must be able to destabilize the fibril state to demonstrate a cytoprotective effect and/or impede the activation of apoptosis. The structure-activity relationships between diclofenac, niflumic acid, nimesulide, and their fibril inhibition activities against hIAPP underline the importance of a negatively charged substituent between the aromatic rings (Fig. 5) . Sulindac has a double bound that can be delocalized easily to provide electrons, considering the electronic resonance. Sulindac has similarity in structure with the exception of an indenyl moiety, suggesting that the benzene ring could be substituted by a fused ring or heterocyclic aromatic ring. Amyloid inhibitors bear aromatic moieties that can potentially be stacked between other aromatic residues from the protein and abrogate the self-assembly of oligomers (Cheng et al. 2013; Frydman-Marom et al. 2011; Hard and Lendel 2012; Porat et al. 2006) . The aromatic structure found in the diarylamine (second column However, it has been extensively used in veterinary medicine (Kahn et al. 2010) .
Chemical modification will be required not only to improve its efficacy toward hIAPP fibrillization but to modify the toxicologic effect in humans.
The present in vitro study demonstrates that several NSAIDs inhibit amyloid formation. Multiple probes were used to study the inhibition of the toxic hIAPP assembly. It has been reported that oligomers are important entities involved in the mechanism of hIAPP amyloid cytotoxicity. D r a f t Table 4 . Fibrillar aggregation properties of hIAPP incubated with different drug treatments at 100 µM, molar ratio 1:10. Data were obtained using a shorter agitation.
Standard deviation for each parameter was calculated.
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